Nichols & Pratt Advisers LLP MA Has $985,000 Position in Danaher Co. (DHR)

Nichols & Pratt Advisers LLP MA lowered its position in shares of Danaher Co. (NYSE:DHR) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,609 shares of the conglomerate’s stock after selling 800 shares during the quarter. Nichols & Pratt Advisers LLP MA’s holdings in Danaher were worth $985,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. ETRADE Capital Management LLC boosted its holdings in shares of Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares during the last quarter. Roundview Capital LLC boosted its holdings in shares of Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares during the last quarter. Honeywell International Inc. boosted its holdings in shares of Danaher by 113.4% in the 3rd quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after purchasing an additional 340,100 shares during the last quarter. Veritable L.P. boosted its holdings in shares of Danaher by 28.2% in the 2nd quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after purchasing an additional 8,912 shares during the last quarter. Finally, Wealthfront Inc. boosted its holdings in shares of Danaher by 10.2% in the 2nd quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock valued at $1,230,000 after purchasing an additional 1,348 shares during the last quarter. Hedge funds and other institutional investors own 75.88% of the company’s stock.

A number of brokerages have weighed in on DHR. Cowen reiterated a “buy” rating and issued a $110.00 price target on shares of Danaher in a report on Tuesday, January 30th. Credit Suisse Group lifted their price target on shares of Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Royal Bank of Canada reiterated a “hold” rating and issued a $98.00 price target on shares of Danaher in a report on Wednesday, January 31st. Stifel Nicolaus lifted their price target on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Morgan Stanley lifted their price target on shares of Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $100.68.

In other news, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the completion of the sale, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Daniel L. Comas sold 62,989 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the sale, the chief financial officer now directly owns 227,805 shares of the company’s stock, valued at $23,226,997.80. The disclosure for this sale can be found here. Insiders sold a total of 237,043 shares of company stock valued at $24,194,886 in the last three months. Insiders own 12.20% of the company’s stock.

Shares of Danaher Co. (NYSE:DHR) opened at $94.79 on Thursday. Danaher Co. has a one year low of $78.97 and a one year high of $104.82. The stock has a market cap of $66,850.00, a price-to-earnings ratio of 27.46, a P/E/G ratio of 2.00 and a beta of 1.04. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the firm posted $1.05 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. analysts expect that Danaher Co. will post 4.37 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Thursday, December 28th. Danaher’s payout ratio is currently 16.00%.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/02/15/nichols-pratt-advisers-llp-ma-has-985000-position-in-danaher-co-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply